BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27765855)

  • 1. Molecular Drug Imaging:
    Jansen MH; Veldhuijzen van Zanten SEM; van Vuurden DG; Huisman MC; Vugts DJ; Hoekstra OS; van Dongen GA; Kaspers GL
    J Nucl Med; 2017 May; 58(5):711-716. PubMed ID: 27765855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models.
    Jansen MH; Lagerweij T; Sewing AC; Vugts DJ; van Vuurden DG; Molthoff CF; Caretti V; Veringa SJ; Petersen N; Carcaboso AM; Noske DP; Vandertop WP; Wesseling P; van Dongen GA; Kaspers GJ; Hulleman E
    Mol Cancer Ther; 2016 Sep; 15(9):2166-74. PubMed ID: 27325687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 89Zr-bevacizumab PET imaging in primary breast cancer.
    Gaykema SB; Brouwers AH; Lub-de Hooge MN; Pleijhuis RG; Timmer-Bosscha H; Pot L; van Dam GM; van der Meulen SB; de Jong JR; Bart J; de Vries J; Jansen L; de Vries EG; Schröder CP
    J Nucl Med; 2013 Jul; 54(7):1014-8. PubMed ID: 23651946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiregional Tumor Drug-Uptake Imaging by PET and Microvascular Morphology in End-Stage Diffuse Intrinsic Pontine Glioma.
    Veldhuijzen van Zanten SEM; Sewing ACP; van Lingen A; Hoekstra OS; Wesseling P; Meel MH; van Vuurden DG; Kaspers GJL; Hulleman E; Bugiani M
    J Nucl Med; 2018 Apr; 59(4):612-615. PubMed ID: 28818988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.
    den Hollander MW; Bensch F; Glaudemans AW; Oude Munnink TH; Enting RH; den Dunnen WF; Heesters MA; Kruyt FA; Lub-de Hooge MN; Cees de Groot J; Pearlberg J; Gietema JA; de Vries EG; Walenkamp AM
    J Nucl Med; 2015 Sep; 56(9):1310-4. PubMed ID: 26135113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease.
    Oosting SF; van Asselt SJ; Brouwers AH; Bongaerts AH; Steinberg JD; de Jong JR; Lub-de Hooge MN; van der Horst-Schrivers AN; Walenkamp AM; Hoving EW; Sluiter WJ; Zonnenberg BA; de Vries EG; Links TP
    J Nucl Med; 2016 Aug; 57(8):1244-50. PubMed ID: 27173161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
    Menke-van der Houven van Oordt CW; Gootjes EC; Huisman MC; Vugts DJ; Roth C; Luik AM; Mulder ER; Schuit RC; Boellaard R; Hoekstra OS; van Dongen GA; Verheul HM
    Oncotarget; 2015 Oct; 6(30):30384-93. PubMed ID: 26309164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of
    Tinkle CL; Duncan EC; Doubrovin M; Han Y; Li Y; Kim H; Broniscer A; Snyder SE; Merchant TE; Shulkin BL
    J Nucl Med; 2019 Mar; 60(3):312-319. PubMed ID: 30072503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of
    Zukotynski KA; Vajapeyam S; Fahey FH; Kocak M; Brown D; Ricci KI; Onar-Thomas A; Fouladi M; Poussaint TY
    J Nucl Med; 2017 Aug; 58(8):1264-1269. PubMed ID: 28360212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants.
    Meyer JP; Edwards KJ; Kozlowski P; Backer MV; Backer JM; Lewis JS
    J Nucl Med; 2016 Nov; 57(11):1811-1816. PubMed ID: 27390161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Distinct Advantage to Intraarterial Delivery of
    Lesniak WG; Chu C; Jablonska A; Du Y; Pomper MG; Walczak P; Janowski M
    J Nucl Med; 2019 May; 60(5):617-622. PubMed ID: 30315146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
    Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
    J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
    van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
    Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models.
    Kossatz S; Carney B; Schweitzer M; Carlucci G; Miloushev VZ; Maachani UB; Rajappa P; Keshari KR; Pisapia D; Weber WA; Souweidane MM; Reiner T
    Cancer Res; 2017 Apr; 77(8):2112-2123. PubMed ID: 28108511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.
    van Asselt SJ; Oosting SF; Brouwers AH; Bongaerts AH; de Jong JR; Lub-de Hooge MN; Oude Munnink TH; Fiebrich HB; Sluiter WJ; Links TP; Walenkamp AM; de Vries EG
    J Nucl Med; 2014 Jul; 55(7):1087-92. PubMed ID: 24790218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
    Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
    J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Zheng KH; Kroon J; Schoormans J; Gurney-Champion O; Meijer SL; Gisbertz SS; Hulshof MCCM; Vugts DJ; van Dongen GAMS; Coolen BF; Verberne HJ; Nederveen AJ; Stroes ESG; van Laarhoven HWM
    J Nucl Med; 2022 Dec; 63(12):1880-1886. PubMed ID: 35738904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T2-weighted images are superior to other MR image types for the determination of diffuse intrinsic pontine glioma intratumoral heterogeneity.
    Harward S; Harrison Farber S; Malinzak M; Becher O; Thompson EM
    Childs Nerv Syst; 2018 Mar; 34(3):449-455. PubMed ID: 29151166
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    van Es SC; Brouwers AH; Mahesh SVK; Leliveld-Kors AM; de Jong IJ; Lub-de Hooge MN; de Vries EGE; Gietema JA; Oosting SF
    J Nucl Med; 2017 Jun; 58(6):905-910. PubMed ID: 28082434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
    McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
    J Neurosurg Pediatr; 2021 Aug; 28(4):371-379. PubMed ID: 34359048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.